Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
Status:
Recruiting
Trial end date:
2024-09-13
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well cabozantinib and pembrolizumab work for the first-line
treatment of patients with liver cancer who are not eligible for local therapy (i.e. advanced
stage). Cabozantinib may stop the growth of tumor cells by blocking some cell surface
receptors and signaling pathways inside the tumor cells. Immunotherapy with monoclonal
antibodies, such as pembrolizumab, may help the body's immune system attack the cancer.
Giving cabozantinib and pembrolizumab together may work better in treating patients with
advanced liver cancer compared to cabozantinib or pembrolizumab alone.